ViroPharma ( VPHM) is a global biotechnology company focused on the development and commercialization of products that address diseases, with a focus on products used by physician specialists or in hospital settings. This stock is trading up 0.12% to $28.28 in recent trading after hitting a 52-week high of $29.10 earlier today. Today's Range: $28.66-$29.10 52-Week Range: $14.62-$28.79 Volume: 1.1 million Three-Month Average Volume: 1 million ViroPharma has a market cap of $2.03 billion and an enterprise value of $1.68 billion. This stock trades at a trailing price-to-earnings of 19.29 and a forward price-to-earnings of 19.15. Its estimated growth rate for this year is -4%, and for next year it's pegged at 4.2%. The current short interest as a percentage of the float for ViroPharma is rather high at 12.5%. Shares of VPHM are hitting new highs today after the company said it expects product sales of $600 million to $660 million this year, which is higher than previous Wall Street estimates. >>8 Stocks Rising on Huge Volume From a technical standpoint, VPHM has started to flirt with a breakout trade today since the stock was briefly trading above some near-term overhead resistance at $28.34 on solid volume. Traders should now look for a sustained high-volume move and close above $28.34 to signal that this stock wants to break out and make a run at its next significant overhead resistance level near $40. Look for a close today on VPHM that's near its daily highs and look for volume that's well above 1 million shares. If we get that action, then traders should look for long biased trades as long as VPHM continues to trend above $28.34.
Irish pharmaceuticals company Shire said on Friday it had arranged to hand its Dermagraft skin substitute to Organogenesis and take a $650 million loss on the disposal, which unwinds a major part of an acquisition it made less than three years ago.